Quarterly Results
VALN Earnings Forecast
Looking ahead, VALN remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of undefined.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -5.54%, while EPS estimates have been Revise Downward by -7.22%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 5.97% . These revisions correlate with a -11.40% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in VALN long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency:

No data
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how VALN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VALN sees a -3.68% change in stock price 10 days leading up to the earnings, and a -0.83% change 10 days following the report. On the earnings day itself, the stock moves by +3.33%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 1.06% on the day following the earnings release and then changed by 4.34% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of VALN's latest earnings report for ?
VALN reported its earnings on 2025-11-20, showcasing a revenue of 29.41M against an estimate of 39.10M, resulting in a -24.79% surprise. The EPS was 0, surpassing the expected -0.3 by 0% . The stock experienced a -1.95% price change on the earnings day and a 0.46% change over the next five days, reflecting market reactions to the results.
How did VALN's stock price react after the earnings release?
Following VALN's earnings announcement on 2025-11-20, the stock price moved by -1.95% on the day of the release. Over the subsequent five days, it saw a 0.46% change. Historically, VALN's stock price tends to shift by an average of -3.68% in the 10 days leading up to earnings and -0.83% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for VALN for undefined?
For , analysts estimate VALN’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -5.54% and EPS estimates Revise Upward by 5.97% over the past three months, indicating analyst expectation in the company’s performance.
How does VALN's stock price correlate with earnings forecast revisions?
The correlation between VALN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -5.54%, while EPS estimates moved Revise Upward by 5.97% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from VALN's next earnings report?
Based on historical trends, VALN's stock price typically moves by -3.68% in the 10 days before its earnings and -0.83% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.
What is the sentiment in Valneva SE (VALN) Q3 2025 Earnings Call Summary?
The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.

